- Biotech firm speaking to advisers about potential acquisition
- Reata has approved drug for rare neurological condition
Biogen is in transition as it attempts to broaden its focus and come up with new growth sources.
Photographer: Adam Glanzman/BloombergUpdated on
Biogen Inc. is exploring an acquisition of Reata Pharmaceuticals Inc., according to people familiar with the matter, in a move that would potentially expand the biotech company’s rare disease treatments.
Cambridge, Massachusetts-based Biogen has been speaking to advisers about a possible purchase of the company, the people said, asking not to be identified because the information is private. Reata, which is also speaking to advisers, may attract interest from other suitors, according to the people.
Up Next
Biogen Weighs Takeover of $4 Billion Drugmaker Reata